Gilead Sciences (GILD): HIV dominance at a fair price

Gilead Sciences (ticker: GILD) is a Foster City, California-based biopharmaceutical company 1 whose revenue is built on two pillars: a dominant HIV franchise and a growing oncology portfolio. HIV products generated $20.8 billion in FY2025 revenue — 71% of total product sales — led by Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, a once-daily single-tablet regimen) and Descovy (emtricitabine/tenofovir alafenamide, used in both HIV treatment and HIV pre-exposure prophylaxis). 2

Beyond HIV, Gilead has been expanding into oncology through Trodelvy (sacituzumab govitecan, an antibody-drug conjugate for metastatic breast and urothelial cancers), cell therapies Yescarta and Tecartus, and three acquisitions closed or announced in early 2026 — Arcellx, Tubulis, and Ouro Medicines — that are meant to build out the company's oncology and autoimmune pipeline. 1

This daily pick requires three criteria: trailing three-year ROE consistently above 15%, positive free cash flow, and reasonable valuation.

ROE: The honest answer is "two out of three years pass cleanly, and the third year's failure was accounting, not business." FY2023 ROE came in at 26.04% and FY2025 at 41.14% — both well above the threshold. 3 FY2024 GAAP ROE collapsed to 2.62%, but that number is almost entirely explained by two non-cash charges: a $4.66 billion CymaBay acquisition IPR&D write-off and a $4.18 billion impairment on existing in-process R&D. 3 Operating cash flow that same year was $10.8 billion — confirming the underlying business was generating cash normally. The three-year average GAAP ROE works out to 23.27%; the TTM figure as of Q1 2026 stands at 42.33%. 3 The FY2024 dip should be understood as an accounting artifact of acquisition activity, not a deterioration in returns. Investors relying solely on the GAAP figure should be aware of this distinction and form their own judgment.

Free cash flow: Clean pass across all three years. 4

Capital intensity is low: capex was only $563 million against $10.0 billion in operating cash flow in FY2025. 5 The earnings quality ratio (operating cash flow / net income) was 1.18× in FY2025 — cash earnings exceeded reported earnings, a positive signal.

Valuation: Reasonable. Trailing P/E is approximately 17× (various sources range 17.05–17.87×); 6 forward P/E is 15.04× based on consensus estimates. 6 EV/EBITDA is 12.26×. 6 All three multiples look reasonable — details in the valuation section below.

Revenue grew 6.0% in FY2024 and 2.4% in FY2025 against a stiff headwind: Veklury (remdesivir, Gilead's COVID-19 antiviral) fell 49% year over year in FY2025 to $911 million as COVID treatment demand faded. 2 Strip out Veklury and core product sales grew 4% in FY2025. 2 Q1 2026 continued the trend: total revenue $6.96 billion, up 4.4% year over year, with HIV franchise revenues up 10% to $5.03 billion. 1

Within HIV, the growth story has two engines right now. Descovy grew 38% year over year in Q1 2026 to $807 million, driven by rising PrEP (pre-exposure prophylaxis, a regimen taken by HIV-negative individuals to prevent infection) prescriptions. 1 Yeztugo (lenacapavir, a twice-yearly injectable PrEP), which received FDA approval in 2025, added $166 million in its first reported quarter. 1 In oncology, Trodelvy grew 37% year over year to $402 million in Q1 2026. 1

GAAP operating margin recovered from 5.8% in FY2024 (distorted by the same acquisition charges that suppressed ROE) to 34.0% in FY2025 and 37.2% in Q1 2026. 5 Non-GAAP operating margin in FY2025 was 44.8%. 5

For FY2026, Gilead raised its product sales guidance to $30.0–30.4 billion (up from $29.6–30.0 billion set in February). 1 Full-year GAAP EPS is guided to ($3.25)–($2.85) and non-GAAP EPS to ($1.05)–($0.65), both negative — that is explained in the risks section below. 1

Gilead's moat rests on one very hard-to-move number: Biktarvy holds roughly 51% of the global HIV treatment market and more than 52% of the US HIV prescription market. 7 The second-largest competitor, ViiV Healthcare (a GlaxoSmithKline-controlled joint venture), holds approximately 32%. 7 That gap does not close easily: Biktarvy is listed as a preferred first-line regimen in the U.S. Department of Health and Human Services HIV treatment guidelines, which creates physician prescribing inertia and high patient switching costs.

The patent protection extends well beyond what the formal expiry date suggests. Biktarvy's core patent expires in October 2027, but Gilead settled patent litigation with Lupin, Cipla, and Laurus Labs in October 2025, blocking US generic entry until April 1, 2036. 8 That settlement gives the franchise roughly 10 additional years of US market exclusivity.

On profitability metrics that quantify moat, Gilead's gross margin was 79.36% and non-GAAP operating margin was 44.8% in FY2025. 6 These are not pharmaceutical-sector averages; they reflect a company with significant pricing power in a therapeutic category where patients typically remain on treatment indefinitely.

The pipeline also carries near-term catalysts that extend this moat. BIC/LEN — a daily oral single-tablet HIV treatment combining bictegravir and lenacapavir — is under FDA priority review with a PDUFA (Prescription Drug User Fee Act target action) date of August 27, 2026. 1 If approved, it could replace Biktarvy as the next-generation standard of care, keeping revenue within Gilead's portfolio. In oncology, Gilead acquired Arcellx in April 2026 to bring anito-cel (a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma) to a PDUFA date of December 23, 2026. 9

Leverage is moderate. Long-term debt stood at approximately $20.9 billion against stockholders' equity of $23.4 billion at end of Q1 2026, giving a D/E ratio of 0.89×. 1 Interest coverage of 9.8× (FY2025 operating income $10.0 billion / interest expense $1.0 billion) confirms debt service is not a near-term concern. 5 An Altman Z-Score of 4.23 sits well above the 2.99 "safe zone" threshold. 5 Gilead also priced $3 billion of senior unsecured notes on May 14, 2026 at coupons of 4.25–4.60%, indicating ongoing access to investment-grade debt markets. 1

The quarterly dividend is $0.82 per share (annualized yield 2.53% at $129.58), raised from $0.79 per share. 6

At $129.58, GILD's trailing P/E of approximately 17× sits at exactly its five-year historical average (excluding 2024's distorted year when GAAP EPS was compressed to $0.38 by non-cash impairments, sending the P/E ratio above 300×). 10 The stock is priced at its own historical norm — neither discounted nor at a premium relative to its own track record.

Versus peers and sector medians, the picture looks cheaper:

11 12 13 14 15

GILD trades at roughly a 47% discount to the biotech sector's profitable-company P/E median of ~32× and a 22% discount on EV/EBITDA. 11 The most plausible explanation for the discount is HIV revenue concentration — investors price in the risk that a single therapeutic area represents 72% of revenue. Whether that discount is warranted is a judgment call, not a fact; the sector comparison simply tells you what the market is currently charging for it. AlphaSpread's blended DCF and multiples valuation model places Gilead's intrinsic value at $130.21, essentially in line with the current market price. 16

Note: FY2026 forward P/E calculations based on consensus EPS estimates are not meaningful this year because the $11.5 billion one-time IPR&D charge from the Arcellx, Tubulis, and Ouro Medicines acquisitions will produce a negative reported EPS. 1 FY2027 non-GAAP EPS consensus is $9.62 across 23 analysts, implying an effective forward P/E of roughly 13.5× on a go-forward basis — that figure is more informative for valuation purposes than the 2026 number. 17

HIV revenue concentration. Biktarvy alone accounted for 48.4% of Q1 2026 product revenue. 1 HIV products as a whole: 72.4%. That is not diversification. A clinical setback, competitive drug, or pricing shock in the HIV market would materially impair the thesis.

IRA price negotiation. CMS (Centers for Medicare & Medicaid Services) selected Biktarvy on January 27, 2026 for the third cycle of Medicare drug price negotiation under the Inflation Reduction Act. 18 Leerink Partners estimates Biktarvy's Medicare sales at approximately 8% of Gilead's 2027 total revenue — the highest relative exposure among all drugs selected in this cycle. 18 Negotiated prices take effect in early 2028. The actual discount won't be known until negotiations conclude.

$11.5 billion one-time acquisition charge. Three concurrent acquisitions (Arcellx at $7.8 billion equity value, Tubulis at approximately $5 billion, Ouro Medicines at $1.675 billion upfront split with Galapagos) will each trigger an IPR&D write-off under GAAP rules when acquiring pre-revenue drug candidates. 9 The aggregate non-cash charge pulls FY2026 GAAP EPS into ($3.25)–($2.85) and non-GAAP EPS into ($1.05)–($0.65). 1 The acquisitions also raise the execution risk of integrating three new organizations simultaneously. This charge does not affect cash flow, but it will generate headline EPS misses throughout 2026.

TIGIT program failure. Gilead's collaboration with Arcus Biosciences on TIGIT checkpoint inhibitors ended badly: Phase 3 STAR-121 (domvanalimab in first-line non-small cell lung cancer) was discontinued for futility on April 20, 2026, following the earlier STAR-221 failure in December 2025. 19 TIGIT as a drug target has now been largely abandoned across the industry. The financial impact is sunk R&D cost rather than lost revenue, but it represents years of oncology pipeline investment that produced nothing.

Cell therapy decline. Yescarta and Tecartus (CAR-T therapies for lymphoma and leukemia) combined fell 12% year over year to $407 million in Q1 2026, with Yescarta down 14% to $332 million. 1 Competitive pressure from newer CAR-T products and bispecific antibodies is the driver. Anito-cel (BCMA target, PDUFA Dec 23, 2026) is intended to reposition Gilead in cell therapy, but commercial execution in that market is notoriously difficult. 9

Insider selling; no purchases. Over the past six months (November 2025 – May 2026), Gilead insiders completed zero open-market purchases and approximately $55.9 million in sales across 25 transactions. 20 All sales were executed under pre-arranged Rule 10b5-1 trading plans — that structure removes timing discretion and limits what can be inferred. CEO Daniel O'Day's largest sales in January and February 2026 involved exercising deep-in-the-money options (strike ~$66) at market prices of $135–$150, which is standard profit-taking rather than a sell signal about business prospects. 20 Nonetheless, the absence of any insider buying over a six-month window at what management would presumably consider discounted prices is worth noting.

Past legal settlement. In April 2025, Gilead paid $202 million to resolve DOJ allegations that it paid kickbacks to physicians via speaker program honoraria between 2011 and 2017 to drive HIV drug prescriptions. 21 The settlement is resolved; the ongoing monitoring and reputational dimensions are for investors to weigh.

Of 22 analysts covering GILD, 51 rate it Buy and 10 rate it Hold; none rate it Sell. 17 The average 12-month price target is $159.95, implying approximately 23.4% upside from the May 15 close of $129.58. 17 The high end of the target range is $180.00 and the low is $122.00. 17

Two recent revisions illustrate the split in market thinking: Morgan Stanley (analyst Terence Flynn) lowered its price target from $175 to $168 while maintaining an Overweight rating on May 13, 2026 — constructive on the pipeline but noting acquisition integration risk. 17 Truist raised its target from $155 to $157 with a Buy rating on May 11, citing HIV franchise momentum and the Yeztugo launch. 17

The massive downward EPS revisions over the past 30 days — 17 analyst downgrades on FY2026 consensus — are entirely a mechanical reflection of the $11.5 billion IPR&D charge being priced into models, not a change in analysts' views on the underlying business. 22 The next test is Q2 2026 results, scheduled for July 30, 2026 after market close. 17

Analyst target prices have a well-documented tendency toward optimism — they consistently overestimate forward returns. The $159.95 consensus target is included here as a reference point, not an endorsement.

The case for GILD is straightforward to state: a company generating $9–10 billion in annual free cash flow, holding more than half the global HIV treatment market, priced at 17× trailing earnings — which also happens to be exactly its five-year historical average — and carrying three near-term pipeline binary events (BIC/LEN PDUFA August 27, anito-cel PDUFA December 23, FY2027 EPS recovery from one-time charges). The market's current pricing appears to reflect the HIV concentration risk and the FY2026 headline-EPS disruption without much credit for pipeline execution.

The uncertainty is real: 72% HIV revenue dependence is high, the IRA negotiation for Biktarvy introduces a quantifiable headwind starting 2028 (~8% of revenue at risk), and the simultaneous integration of three acquisitions is genuinely demanding. None of those risks is hidden — they're priced in to varying degrees. Whether the current balance tips toward opportunity or risk depends on how investors weigh the durability of the HIV moat against the concentration and regulatory exposure. This pick clears the three hard screens and offers enough documented data to start that analysis.